deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03692065

API-CAT STUDY for APIxaban Cancer Associated Thrombosis (API-CAT)

Long-term Treatment of Cancer Associated VTE: Reduced vs Full Dose of Apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Cancer-associated Thrombosis
Interventions Apixaban 5 MG
Updated 15 times since 2018 Last updated: Feb 4, 2025 Started: Oct 11, 2018 Primary completion: Sep 6, 2024 Completion: Oct 20, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Cancer-associated Thrombosis, this trial is completed. The trial is conducted by Assistance Publique - Hôpitaux de Paris and has accumulated 15 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Sep 2022 · 18 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Aug 2023 · 7 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Dec 2024 — Mar 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 10 earlier versions

  1. Oct 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  3. Jan 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  4. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  5. Mar 2021 — Sep 2022 [monthly]

    Recruiting PHASE3

  6. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  7. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  8. Jun 2019 — Jan 2021 [monthly]

    Recruiting PHASE3

  9. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  10. Nov 2018 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Assistance Publique - Hôpitaux de Paris
  • Bristol-Myers Squibb
Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albacete, Spain , Alicante, Spain , Amiens, France , Amsterdam, Netherlands , Angers, France , Apeldoorn, Netherlands , Arras, France , Athens, Greece , Avignon, France , Barcelona, Spain and 76 more locations